Compare MHF & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MHF | ENTX |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.3M | 147.4M |
| IPO Year | N/A | 2015 |
| Metric | MHF | ENTX |
|---|---|---|
| Price | $6.79 | $2.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 61.8K | ★ 421.3K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.63 | $0.91 |
| 52 Week High | $7.64 | $4.20 |
| Indicator | MHF | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 53.32 |
| Support Level | $6.65 | $2.66 |
| Resistance Level | $7.04 | $3.10 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 5.56 | 28.41 |
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.